Breast Cancer 21 Gene Test And Early Luminal A Patients Treatment Decision Selection Study

ObjectiveThe treatment of breast cancer is mainly surgery,chemotherapy,radiotherapy,endocrine therapy and targeted therapy are important adjuvant therapy.In recent years,immunotherapy in the treatment of breast cancer has also been highly valued,and gradually applied in clinical.The comprehensive application of the above methods has greatly reduced the recurrence rate and mortality of breast cancer.With the continuous development of diagnosis and treatment technology,the number of patients with early breast cancer is increasing.How to choose postoperative adjuvant therapy for many patients with low recurrence risk of Luminala type breast cancer has become the focus of attention.In recent years,some scholars have found that 21 gene detection and relapse score(RS)have very important guiding significance in the selection of adjuvant therapy for patients with early Luminala type breast cancer,which has been confirmed through a large number of clinical data,and has been included in various versions of breast cancer treatment guidelines as a diagnosis and treatment standard.The blindness in the selection of treatment options for early Luminala type breast cancer patients was avoided,and the damage and burden caused by blind chemotherapy for early Luminala type breast cancer patients were reduced.However,there has not been much clinical application of gene 21 detection,and it has not been paid much attention by many clinicians.Therefore,this paper studied the significance of 21 gene detection in treatment plan decision-making for patients with early Luminala type breast cancer,so as to provide more accurate treatment decision and prognosis information for patients with early Luminala type breast cancer,and avoid the waste of medical resources and excessive treatment for patients.MethodsA total of 174 patients with early Luminala breast cancer diagnosed in the Breast Surgery Department of the First Affiliated Hospital of Chifeng University in Inner Mongolia from January 2017 to December 2019 were selected strictly according to the inclusion criteria.The basic data of the breast cancer patients were collected,including age of onset,histological grade,menstrual status,number and diameter of malignant tumors,and the presence of vascular cancer emboli.Patients were divided into low risk group and medium/high risk group.The recurrence scores were analyzed according to the 21 gene test technology,and treatment decisions were taken before and after the recurrence scores,so as to clarify the significance of 21 gene test.ResultsA total of 174 patients with early Luminala type breast cancer were analyzed and their recurrence risk scores were obtained by 21 gene detection.Before 21 genetic testing can be carried out by the traditional recurrence risk assessment,there are 108 cases of breast cancer patients(62.0%)of early luminal A type,recommend the use of adjuvant chemotherapy sequential treatment of endocrine therapy,and improve the 21 after genetic testing,of which 66 cases(37.9%)patients changed to pure endocrine treatment,42cases(24.1%)patients for adjuvant chemotherapy sequential endocrine therapy still(P = 0.001),make avoided chemotherapy in 61% of patients,showed that21 important guiding value in clinic,genetic testing.The study also showed: the size of the risk of recurrence score of 21 genetic testing and the incidence of breast cancer patients age,histologic grading,female menstruation status,malignant tumors in patients with no significant correlation between the number and diameter size,and so on and so forth,but with the state of Ki-67(P = <0.0001),and presence of vascular tumor emboli(P = 0.0062).ConclusionsFor patients with early Luminala breast cancer,the recurrence risk score can be obtained by 21 gene detection and the treatment plan can be changed according to the recurrence risk score,so as to avoid the risk of unnecessary adjuvant chemotherapy for patients,and develop a more precise individualized treatment,providing a strong guarantee for the treatment of patients with early Luminala breast cancer.